Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

As Delhi’s AQI hits a new high, it is essential to know the effect it can have on our skin. Know the preventive measures from ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...

Two studies assessed the quality and accuracy of ChatGPT recommendations for atopic dermatitis based on their concordance with clinical guidelines.

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

We are building out the ZORYVE product label with the expected approval of scalp and body psoriasis in the middle of 2025 as ...